ID   MM33
AC   CVCL_4D16
DR   cancercelllines; CVCL_4D16
DR   Wikidata; Q54906103
RX   PubMed=24994677;
CC   Doubling time: 91 hours (PubMed=24994677).
CC   Sequence variation: Mutation; HGNC; HGNC:4390; GNAQ; Simple; p.Gln209Pro (c.626A>C); ClinVar=VCV000375957; Zygosity=Unspecified (PubMed=24994677).
CC   Omics: SNP array analysis.
CC   Derived from site: Metastatic; Skin; UBERON=UBERON_0002097.
ST   Source(s): PubMed=24994677
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 8
ST   D16S539: 11,12
ST   D21S11: 31.2,32.2
ST   D5S818: 11,12
ST   D7S820: 10,11
ST   TH01: 6,8
ST   TPOX: 11
ST   vWA: 15
DI   NCIt; C7712; Uveal melanoma
DI   ORDO; Orphanet_39044; Uveal melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 22-09-15; Last updated: 19-12-24; Version: 11
//
RX   PubMed=24994677; DOI=10.1016/j.molonc.2014.06.004; PMCID=PMC5528590;
RA   Amirouchene-Angelozzi N., Nemati F., Gentien D., Nicolas A.,
RA   Dumont A., Carita G., Camonis J., Desjardins L., Cassoux N.,
RA   Piperno-Neumann S., Mariani P., Sastre-Garau X., Decaudin D.,
RA   Roman-Roman S.;
RT   "Establishment of novel cell lines recapitulating the genetic
RT   landscape of uveal melanoma and preclinical validation of mTOR as a
RT   therapeutic target.";
RL   Mol. Oncol. 8:1508-1520(2014).
//